Primidone

  • P. N. Patsalos
Chapter

Abstract

Primidone (Fig. 1) corresponds chemically to 5-ethyldihydro-5-phenyl-4,6(1-H,5H)pyrimidine-dione with an empirical formula of C12H14N2O2 and a molecular weight of 218.25.

References

  1. 1.
    Syversen GB, Morgan JP, Weintraub M, Myers GJ. Acetazolamide-induced interference with primidone absorption. Case reports and metabolic studies. Arch Neurol. 1977;34:80–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Battino D, Avanzini G, Bossi L, Croci D, Cusi C, Gomeni C, Moise A. Plasma levels of primidone and its metabolite phenobarbital: effect of age and associated therapy. Ther Drug Monit. 1983;5:73–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Theis JGW, Koren G, Daneman R, Sherwin AL, Menzano E, Cortez M, Hwang P. Interactions of clobazam with conventional antiepileptics in children. J Child Neurol. 1997;12:208–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Nanda RN, Johnson RH, Keogh HJ, Lambie DG, Melville ID. Treatment of epilepsy with clonazepam and its effect on other anticonvulsants. J Neurol Neurosurg Psychiatry. 1977;40:538–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (lamictal) for refractory partial seizures. Epilepsia. 1989;30:356–63.PubMedCrossRefGoogle Scholar
  6. 6.
    Perucca E, Baltes E, Ledent E. Levetiracetam: absence of pharmacokinetic interactions with other antiepileptic drugs (AEDs). Epilepsia. 2000;41(Suppl):150.Google Scholar
  7. 7.
    Browne TR, Feldman RG, Buchanan RA, Allen NC, Fawcett-Vickers L, Szabo GK, Mattson GF, Norman SE, Greenblatt DJ. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983;33:414–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Fincham RW, Schottelius DD, Sahs AL. The influence of diphenylhydantoin on primidone metabolism. Arch Neurol. 1974;30:259–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Levy RH, Loiseau P, Guyot M, Blehaut H, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36:661–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Summary of product characteristics – Sulthiame/Ospolot. 2009.Google Scholar
  11. 11.
    Doose DR, Walker SA, Pledger G, Lim P, Reife RA. Evaluation of phenobarbital and primidone/phenobarbital (primidone active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multicenter, double-blind, placebo controlled trials in outpatients with partial seizures. Epilepsia. 1995;36 (Suppl 3):158.Google Scholar
  12. 12.
    Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, Penry JK. Mechanism of valproate–phenobarbital interaction in epileptic patients. Clin Pharmacol Ther. 1981;29:480–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Matilainen R, Pitkanen A, Ruutiainen T, et al. Effect of vigabatrin on epilepsy in mentally retarded patients: a 7-month follow-up study. Neurology. 1988;38:743–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, Egli M, Basuer G, Stenzel E, Blankenhorn V. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15:67–73.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations